Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05RBH
|
|||
| Former ID |
DNCL003664
|
|||
| Drug Name |
N9-GP
|
|||
| Synonyms |
NN7999
Click to Show/Hide
|
|||
| Indication | Factor IX deficiency [ICD-11: 3B11; ICD-10: D67; ICD-9: 286.1] | Phase 1 | [1] | |
| Company |
Novo Nordisk
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Coagulation factor IX (F9) | Target Info | Modulator | [2] |
| KEGG Pathway | Complement and coagulation cascades | |||
| Panther Pathway | Blood coagulation | |||
| Pathwhiz Pathway | Coagulation | |||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
| Intrinsic Pathway of Fibrin Clot Formation | ||||
| Gamma-carboxylation of protein precursors | ||||
| Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus | ||||
| Removal of aminoterminal propeptides from gamma-carboxylated proteins | ||||
| WikiPathways | Complement and Coagulation Cascades | |||
| PTM: gamma carboxylation, hypusine formation and arylsulfatase activation | ||||
| Blood Clotting Cascade | ||||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01395810) Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773. U.S. National Institutes of Health. | |||
| REF 2 | Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011 Sep 8;118(10):2695-701. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.